The Sound of Evolution
Axitinib
Mechanism of action:
Axitinib is a small-molecule tyrosine kinase inhibitor. It selectively inhibits the tyrosine kinase activity of the vascular endothelial growth factor receptor (VEGFR) family, including VEGFR-1, VEGFR-2, and VEGFR-3. By blocking VEGF signaling, axitinib suppresses tumor-associated angiogenesis and blood supply signaling, thereby inhibiting tumor cell growth.
Reference(s):
1. Cohen EE et al. (2008). Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol.
2. Inai T et al. (2004). Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol.
3. Rugo HS et al. (2005). Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol.